CLINICAL TRIALS PROFILE FOR PROBUCOL
✉ Email this page to a colleague
All Clinical Trials for PROBUCOL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00276133 ↗ | Effects of Atorvastatin Versus Probucol on Small Dense LDL | Completed | Yokohama City University Medical Center | Phase 4 | 2004-01-01 | Small dense low-density lipoprotein (LDL) plays an important role in causing glomerular injury through conversion to an oxidatively modified form of LDL. However, few studies evaluated the effects of antilipidemic agents on the LDL particle size and renoprotective actions in hyperlipidemic patients with non-diabetic nephropathy. |
| NCT00426348 ↗ | A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy | Completed | Guangdong General Hospital | Phase 4 | 2007-05-01 | a statement of the study hypothesis:the effect of valsartan in patients with IgA nephropathy have been proved,and the efficacy of probucol in combination with valsartan is to be proved in patients with IgA nephropathy. This is a prospective randomized controlled, double blinded pilot study to identify the efficacy of probucol in combination with valsartan in patients with IgA nephropathy. The renal function deterioration will be the primary outcome studied. The expected study duration will be 36 months. |
| NCT00426348 ↗ | A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy | Completed | Guangdong Provincial People's Hospital | Phase 4 | 2007-05-01 | a statement of the study hypothesis:the effect of valsartan in patients with IgA nephropathy have been proved,and the efficacy of probucol in combination with valsartan is to be proved in patients with IgA nephropathy. This is a prospective randomized controlled, double blinded pilot study to identify the efficacy of probucol in combination with valsartan in patients with IgA nephropathy. The renal function deterioration will be the primary outcome studied. The expected study duration will be 36 months. |
| NCT00549978 ↗ | Safety and Pharmacokinetics of Probucol and Cilostazol | Completed | Otsuka Pharmaceutical Co., Ltd. | Phase 4 | 2007-10-01 | to investigate the safety and pharmacokinetics, in healthy adult male subjects |
| NCT00549978 ↗ | Safety and Pharmacokinetics of Probucol and Cilostazol | Completed | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 4 | 2007-10-01 | to investigate the safety and pharmacokinetics, in healthy adult male subjects |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PROBUCOL
Condition Name
Clinical Trial Locations for PROBUCOL
Clinical Trial Progress for PROBUCOL
Clinical Trial Phase
Clinical Trial Sponsors for PROBUCOL
Sponsor Name
